STUDY OF PHYSICAL AND SOCIO-ECONOMIC ACCESSIBILITY OF ANTI-TUMOR DRUGS OF THE L01AX GROUP «OTHER ALKYLATING AGENTS» IN UKRAINE
DOI:
https://doi.org/10.11603/2312-0967.2025.1.15278Keywords:
temozolomide, dacarbazine, monthly monitoring, physical and socio-economic accessibility of drugs, marketing analysisAbstract
The aim of the work: conducting a marketing analysis of anticancer drugs temozolomide (L01AX03) and dacarbazine (L01AX04) of the L01AX group «Other alkylating agents» to establish their physical and socio-economic accessibility for cancer patients in Ukraine.
Materials: State Register of Drugs of Ukraine, pharmaceutical market according to Proxima Apteka data, socio-economic regulatory lists of medicinal products. Methods: monitoring, analysis, synthesis, comparison, generalization.
Results and Discussion. It was established that as of August 2024, 7 trade names of 29 medicinal products (including dosages) of temozolomide and dacarbazine were registered in Ukraine. All medicinal products were exclusively foreign, with the highest share being German medicinal products (37%). Capsules were the leader in terms of dosage form (74%). The physical presence of only 8 (28%) medicinal products of this group on the pharmaceutical market was detected, of which two trade names (7 medicinal products) of temozolomide: Temomedac (20, 100, 140, 180, 250 mg), Medac, Germany; Temodal (20, 100 mg), Merck Sharp & Dohme Idea, Switzerland and one medicinal product of dacarbazine – Dacarbazine Medac (200 mg), Medac, Germany. For these medicinal products, monthly monitoring of their wholesale prices in hryvnias and US dollars was conducted for 10 months, retail prices were determined, and socio-economic accessibility coefficients were determined: liquidity (Сliq), solvency adequacy (Сas), and accessibility (D).
Conclusions. It was investigated that wholesale prices for the analyzed medicinal products increased monthly. Still, the amplitude of their growth did not proportionally coincide with the dollar growth against the hryvnia. Only in 13% of months the Сliq values of wholesale and retail prices of medicinal products were higher than 0.15. In most medicinal products, the lowest Сas values and the highest D values were in the months with the highest wages during the monitoring period, which indicated the highest socio-economic accessibility of medicines.
A dissonance was established between the presence of medicinal products in the socio-economic regulatory lists of drugs in Ukraine and their physical accessibility on the pharmaceutical market. A total of 6 (21%) medicinal products of this group were included in the List of drugs purchased from the state budget for the implementation of cancer treatment programs. The feasibility of synthesizing domestic new drugs of the L01AX group for treating patients with oncological pathologies has been identified.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. DOI: 10.3322/caac.21834 DOI: https://doi.org/10.3322/caac.21834
Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30. DOI: 10.1002/cncr.33587 DOI: https://doi.org/10.1002/cncr.33587
Guida F, Kidman R, Ferlay J, Schüz J, Soerjomataram I, Kithaka B, et al. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat Med. 2022;28(12):2563–72. DOI: 10.1038/s41591-022-02109-2 DOI: https://doi.org/10.1038/s41591-022-02109-2
Bharti AC, Vishnoi K, Singh SM, Aggarwal BB. Chapter 1 – Pathways linked to cancer chemoresistance and their targeting by nutraceuticals. Role of Nutraceuticals in Cancer Chemosensitization. Volume 2 in Cancer Sensitizing Agents for Chemotherapy. 2018;1-30. DOI: 10.1016/B978-0-12-812373-7.00001-2 DOI: https://doi.org/10.1016/B978-0-12-812373-7.00001-2
Malignant skin melanoma: Unified clinical protocol for primary and specialized medical care [Злоякісна меланома шкіри: Уніфікований клінічний протокол первинної та спеціалізованої медичної допомоги]. Kyiv, Ukraine: The State Expert Center of Ministry of Health of Ukraine. 2023.
Soft tissue sarcomas of the extremities and trunk: Standards of care [Саркоми м’яких тканин кінцівок та тулуба: Стандарти медичної допомоги]. Kyiv, Ukraine: The State Expert Center of Ministry of Health of Ukraine. 2023.
Uterine neoplasms: Evidence-based clinical guideline [Новоутворення матки: Клінічна настанова, заснована на доказах]. Kyiv, Ukraine: The State Expert Center of Ministry of Health of Ukraine. 2023.
Nemchenko AS, Zharkova SO, Podhaina MV. Scientific summary of the results of monitoring prices and availability of anticancer drugs for the treatment of gastric and rectal cancer [Наукове узагальнення результатів моніторингу цін та доступності протипухлинних препаратів для лікування раку шлунку та раку прямої кишки]. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii. 2012;4:60–4.
Panfilova HL, Tsurikova OV. Results of a study of tender procurement of medicines for oncohematological patients in Ukraine [Результати дослідження тендерних закупівель лікарських засобів для онкогематологічних хворих в Україні]. Zaporozhye Medical Journal. 2014;1(82):98–103. DOI: https://doi.org/10.14739/2310-1210.2014.1.23836
Nemchenko AS, Fursa LI. Marketing research on the market of anticancer drugs for the treatment of lung cancer [Маркетингові дослідження ринку протипухлинних препаратів для лікування раку легенів]. Social Pharmacy in Health Care. 2016;2(2):59–67. DOI: https://doi.org/10.24959/sphhcj.16.37
Official website of the State Register of Medicines of Ukraine [Офіційний сайт Державного реєстру лікарських засобів України]. Available from: http://www.drlz.com.ua/
Proxima Apteka [Спеціалізоване інтернет-видання Proxima Apteka]. Available from: https://pharmbase.com.ua/uk/optovi-propozitsiyi/
National Bank of Ukraine. Information page of the web portal [Національний банк України. Інформаційна сторінка веб-порталу]. Available from: https://bank.gov.ua/
Pension Fund of Ukraine. Information page of the web portal [Пенсійний фонд України. Інформаційна сторінка веб-порталу]. Available from: https://www.pfu.gov.ua/
Some issues of state regulation of prices for medicines and medical products: Resolution of the Cabinet of Ministers of Ukraine dated March 25, 2009, №333 [Деякі питання державного регулювання цін на лікарські засоби і вироби медичного призначення: Постанова Кабінету Міністрів України від 25.03.2009 р. №333]. Available from: https://zakon.rada.gov.ua/laws/show/333-2009-%D0%BF#n19
Some issues of procurement of medicines, medical devices, and auxiliary means for them: Resolution of the Cabinet of Ministers of Ukraine dated 07.03.2022 №216 [Деякі питання закупівлі лікарських засобів, медичних виробів та допоміжних засобів до них: Постанова Кабінету Міністрів України від 07.03.2022 р. №216]. Available from: https://zakon.rada.gov.ua/laws/show/216-2022-%D0%BF#Text
List of medicines subject to reimbursement under the program of state guarantees of medical care for the population, as of August 23, 2024: Order of the Ministry of Health of Ukraine dated September 4, 2024 №1537 [Перелік лікарських засобів, які підлягають реімбурсації за програмою державних гарантій медичного обслуговування населення, станом на 23 серпня 2024 року: Наказ Міністерства охорони здоров’я України від 04.09.2024 р. №1537]. Available from: https://www.apteka.ua/reimbursement.
On declaring changes in wholesale prices for medicines as of August 16, 2024: Order of the Ministry of Health of Ukraine dated August 20, 2024, №1461 [Про декларування зміни оптово-відпускних цін на лікарські засоби станом на 16 серпня 2024 року: Наказ Міністерства охорони здоров’я України від 20.08.2024 р. №1461]. Available from: https://moz.gov.ua/uk/decrees/nakaz-moz-ukrayini-vid-20-08-2024-1461-pro-deklaruvannya-zmini-optovo-vidpusknih-cin-na-likarski-zasobi-stanom-na-16-serpnya-2024-roku
On approval of the sixteenth edition of the State Formulary of Medicines and ensuring its availability: Order of the Ministry of Health of Ukraine dated March 12, 2024, №418 [Про затвердження шістнадцятого випуску Державного формуляра лікарських засобів та забезпечення його доступності: Наказ Міністерства охорони здоров’я України від 12.03.2024 р. №418]. Available from: https://moz.gov.ua/uk/decrees/nakaz-moz-ukraini-vid-12032024--418-pro-zatverdzhennja-shistnadcjatogo-vipusku-derzhavnogo-formuljara-likarskih-zasobiv-ta-zabezpechennja-jogo-dostupnosti.
Fedyak IO, Maksymenko OV. Assessment of socio-economic availability of spironolactone diuretics (C03DA01) and furosemide (C03CA01) of the domestic pharmaceutical market. Soc. pharm. health care. 2019;5(1):20–30. DOI: 10.24959/sphhcj.19.140 DOI: https://doi.org/10.24959/sphhcj.19.140
Fediak I, Volosheniuk T. Marketing study of selective serotonin reuptake inhibitors for the treatment of post-traumatic stress disorder in military servants and war veterans. Sci Pharm Sci. 2024;6(52):90–102. DOI: 10.15587/2519-4852.2024.308684 DOI: https://doi.org/10.15587/2519-4852.2024.308684
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
